14 results about "Aesculetin" patented technology

The invention discloses a camelina sativa seed meal oligosaccharide extract capable of regulating blood sugar and a preparation method of the camelina sativa seed meal oligosaccharide extract, and the camelina sativa seed meal oligosaccharide extract is extracted from camelina sativa seed meal through fermentation, heating extraction, cooling alcohol precipitation and enzymolysis. Comprising a camelina seed meal oligosaccharide extract and a cortex fraxini iridoid component extract. The cortex fraxini iridoid component extract is obtained through microwave-assisted enzymolysis extraction and purification; the invention further discloses application of the blood sugar reducing composition in blood sugar reducing food, medicine or health care products. The camelina seed meal oligosaccharide extract, the cortex fraxini iridoid component extract and the hypoglycemic composition have inhibition ability on alpha-glucosidase and alpha-amylase, can improve glucose consumption, glycogen content and glycolysis key enzyme activity, effectively improve insulin resistance, improve oxidative stress, regulate intestinal flora structure, and improve the blood sugar level, so that the hypoglycemic effect of the composition is improved. The traditional Chinese medicine is safe and non-toxic and has a good effect on treating diabetes and complications.

The application discloses a kind of compositions for treating radiation enteropathy and application thereof, belong to medical technology field.The composition includes the following components: anemarrhena asphodeloides B4, obakunine, berberine, aesculetin, fraxinellone and fraxinellin.The composition has no toxic side effects, has good safety, can reduce the inflammatory infiltration of intestinal epithelial cells, reduce intestinal epithelial cell apoptosis, protect intestinal barrier and protect intestinal oxidative damage by regulating NF-κB, Caspase 9 / 3 and NRF2 pathway, and then multi-component, multi-pathway jointly play the efficacy of treating radiation enteropathy.The problem that there is no effective drug for treating radiation enteropathy in the prior art is solved.

The invention relates to a detection method of an infantile cough and asthma composition, and belongs to the technical field of detection. The detection method of the infantile cough and asthma composition comprises the following steps: S1, adding the infantile cough and asthma composition into methanol for reflux, cooling and filtering to obtain a to-be-detected solution; s2, determining the liquid to be detected by adopting a high performance liquid chromatography to obtain the contents of aesculin and aesculetin in the infantile cough and asthma composition, according to the high performance liquid chromatography, a phosphoric acid aqueous solution is used as a mobile phase A, methanol is used as a mobile phase B, and specific elution conditions are adopted. The aesculin and aesculetin obtained by the detection method for the infantile cough and asthma composition are good in peak pattern and can be well separated from front and rear peaks, the detection method which is high in accuracy, good in precision, good in durability and suitable for large-scale production quality control is provided, and detection of main components of the infantile cough and asthma composition can be achieved.

The application discloses an oil control composition containing tea extract and products and applications thereof. The oil control composition containing tea extract comprises a tea extract solution, a vitagenin solution and an aesculetin solution. Researches show that the oil control composition has a good oil control effect, can reduce the intracellular IDH concentration by inhibiting the expression level of IDH, thereby regulating the content of testosterone, and achieving the effect of regulating the secretion of skin oil. Meanwhile, the composition is further prepared into oil control cosmetics and used on the skin, can effectively improve the oil absorption and decontamination capacity, can reduce the adhesion and fluidity with the skin, improve the comfort of the user, has a fresh skin feeling, can remove the overflowed oil on the skin, and can control the oil for a long time, moisturize, and effectively improve the state of oily skin and dry skin. In addition, the raw materials used in the application are easy to obtain, can be extracted from plants, are non-toxic and harmless, and are safer to use.

The invention discloses a construction method of a finger-print spectrum of a styptic capsule and application of the styptic capsule in quality detection, and belongs to the field of Chinese patent medicine detection. The method comprises the following steps: firstly, adding 80% methanol solution into contents of different batches of Xuezhenning capsules for extraction to prepare Xuezhenning capsule test solution; the method comprises the following steps: taking ginsenoside Rg1, notoginsenoside R2, ginsenoside Rd, caffeic acid, isorhamnetin, verbascoside, aesculetin, ferulic acid, rutin and quercetin as reference substances, and preparing a reference substance solution; respectively injecting the test solution and the reference solution into a high performance liquid chromatograph to obtain corresponding chromatograms; performing similarity analysis on the chromatogram of the test solution; and finally, according to the chromatogram of the test solution and the chromatogram of the reference substance solution, combining a total ion chromatogram obtained by the high-resolution mass spectrum and a mass spectrum result map of the chemical components to construct the fingerprint spectrum of the styptic Ning capsule. The method can be used for simultaneously detecting 10 components in the haemostatic Ning capsule, and can be used for accurately, clearly and objectively evaluating the quality of the haemostatic Ning capsule.

The present application belongs to the technical field of quality control of traditional Chinese medicine, and particularly relates to a quality control method of Ledum palustre L. The quality control method provided by the present application comprises the following processes: S1, identification: thin layer chromatography identification is respectively performed by taking ursolic acid, hyperoside, rutin, aesculetin and aesculin as the control; S2, inspection: the moisture content, total ash content, acid insoluble ash content and alcohol-soluble extract content of the medicinal material are determined; S3, content determination: the total content of volatile oil, three five-ring triterpenes (betulinic acid, oleanolic acid and ursolic acid) and two flavonoid glycosides (hyperoside and preussin) in the medicinal material is determined by using high performance liquid chromatography. The present application combines multi-index component analysis and thin layer chromatography identification, has strong specificity and good reproducibility, can comprehensively and effectively control the quality of Ledum palustre L., and ensures the medicinal effectiveness and safety of Ledum palustre L.

The invention aims to provide a method for determining the content of main effective components of liver-protecting Buzufever granules and application, and aims to overcome the defect that the conventional single-component determination method is difficult to comprehensively reflect the overall quality of a preparation and solve the technical problem of lack of accurate quantification of multiple active components at the same time. According to the method, 17 characteristic components such as isopsoralen, scopoletin, aesculetin and the like are simultaneously determined by adopting an ultra-high performance liquid chromatography-tandem mass spectrometry technology and optimizing chromatography and mass spectrometry conditions. According to the technical scheme, higher-throughput and more comprehensive multi-index synchronous quantification is achieved, higher sensitivity and specificity are achieved, linearity is good, precision is high, repeatability and stability meet requirements, and quality evaluation of the complex compound preparation can be accurately and efficiently completed. According to the technical scheme provided by the invention, a more scientific and comprehensive modern quality control standard is established for the liver-protecting Buzufever granules, and the quality controllability and the medication safety guarantee level are remarkably improved.

The invention relates to the technical field of biological medicines, and discloses application of aesculetin in preparation of CD4 + T cell activation inhibition drugs on the first aspect, and the aesculetin reduces CD4 + T cell activation and proliferation by inhibiting T cell receptor (TCR) signal channels so as to inhibit generation of B cell mediated autoantibodies. On the second aspect, the invention discloses an application of aesculetin in preparation of a medicine for preventing and / or treating SLE, and the application is used for preventing and / or treating SLE by inhibiting CD4 + T cell activation. On the third aspect, the invention discloses a pharmaceutical composition which comprises a therapeutically effective amount of aesculetin and one or more pharmaceutically acceptable carriers or auxiliary materials and is used for preventing and / or treating systemic lupus erythematosus or inhibiting CD4 + T cell activation. It is found that aesculetin can effectively inhibit TCR-mediated CD4 + T cell activation, shows a remarkable treatment effect in an SLE model, and fills the blank in the prior art.

The invention discloses application of ziyuglycoside II in preparation of a medicine for treating and relieving acute promyelocytic leukemia and / or ATRA-resistant acute promyelocytic leukemia and a medicine composition, and belongs to the technical field of medicine. Experiments prove that ziyuglycoside II can inhibit proliferation of acute promyelocytic leukemia cells (NB4) and transretinoic acid (ATRA) drug-resistant acute promyelocytic leukemia cells (NB4-R2), induce differentiation of the NB4 and the NB4-R2, promote apoptosis of the NB4-R2 cells and relieve disease development of ATRA drug-resistant cell xenotransplantation acute promyelocytic leukemia. The ziyuglycoside II is developed as a novel drug for resisting acute promyelocytic leukemia or an auxiliary component thereof, and the ziyuglycoside II has obvious effects of resisting acute promyelocytic leukemia and drug-resistant acute promyelocytic leukemia; the invention provides a new approach and means for treating acute promyelocytic leukemia and drug-resistant acute promyelocytic leukemia.

The application provides a separation and purification method of aesculin, aesculetin and aesculin in cortex fraxini, which comprises the following steps: firstly, heating extraction is performed on the crushed cortex fraxini raw material; secondly, plate and frame pressure filtration is performed on the obtained extract, and the filtrate is subjected to chromatographic separation on a macroporous resin column; then, 10-30% ethanol is used for resolving the macroporous resin column and purifying aesculin; subsequently, 50-80% ethanol is used for resolving the macroporous resin column, and the resolving liquid is subjected to enzymolysis and aesculetin purification; finally, the enzymolysis mother liquor is treated and aesculin is purified. The multi-layer separation and purification scheme can simultaneously and efficiently separate and purify the three high-value active components of aesculin, aesculetin and aesculin in cortex fraxini, greatly improves the comprehensive utilization rate of cortex fraxini resources, creates higher product value, reduces the use amount of organic solvents, reduces the production cost, reduces the pollution to the environment, and meets the green and environmental protection production concept.

The invention relates to the technical field of compounds, in particular to an aesculetin derivative, a preparation method of the aesculetin derivative and application of the aesculetin derivative in preparation of drugs for preventing and treating xerophthalmia. According to the aesculetin derivative disclosed by the invention, the water solubility is improved on the basis of an aesculetin mother nucleus. System safety evaluation shows that the ocular surface cytotoxicity is obviously lower than that of a prototype, no obvious cell injury or apoptosis is caused within an effective treatment concentration, and no obvious adverse reaction is caused in a systemic toxicity test. In an animal dry eye model, the derivative has better effects of increasing tear secretion, prolonging tear film rupture time, reducing cornea staining score, improving symptoms and repairing ocular surface injury than existing drugs, and takes effect faster.

The invention discloses an aesculetin extraction method and application of aesculetin in plant disease control, and belongs to the technical field of plant disease control, the extraction method comprises the following steps: (1) raw material pretreatment: crushing and sieving a cortex fraxini raw material to obtain cortex fraxini powder; (2) extraction treatment: mixing the cortex fraxini powder with a methanol solution to obtain a mixed solution, then placing the mixed solution in an ultrasonic cleaner for extraction to obtain an extracting solution after the extraction is finished, transferring the extracting solution into a water bath heating reflux device, and after the reaction is finished, carrying out reduced pressure suction filtration while the extracting solution is hot to obtain aesculetin. And the application field is narrow. Meanwhile, the aesculetin is proved to have a broad-spectrum induced resistance effect and can effectively prevent and treat various diseases such as tobacco bacterial wilt, target leaf spot and virus diseases.

The invention discloses an application of agrimonolide in preparation of a medicine for treating cholestatic liver diseases. It is found for the first time that the agrimonolide promotes bile acid efflux by up-regulating expression and / or functions of bile acid efflux transporter, so that small bile duct hyperplasia is inhibited, hepatic fibrosis is reduced, macrophage infiltration is relieved, a unique liver protection effect is generated, and a new medication strategy is brought to treatment of cholestatic liver diseases.

The invention belongs to the technical field of medicinal material identification, and particularly relates to application of aesculetin, farrerol and genkwanin to identification of a Korean medicine hepatitis grass wine roasted product. According to the method, thin-layer identification is carried out on the wine-fried product of the Korean medicine hepatitis grass, meanwhile, the contents of water, total ash, acid-insoluble ash, extracts and effective components are detected, and the quality standard of the Korean medicine hepatitis grass is established. In addition, the processing technology of the wine-roasted Korean medicine hepatitis grass is studied, and the optimal wine-roasted technological conditions are screened out. And finally, carrying out acute toxicity experiments on the Korean medicine hedychium japonicum and the wine-fried product thereof, and proving that the Korean medicine hedychium japonicum and the wine-fried product thereof basically have no acute toxicity. In conclusion, the invention provides a theoretical basis for formulating the quality standard of the Korean medicine hepatitis grass and the wine-fried product thereof, and lays a solid foundation for the development of subsequent innovative traditional Chinese medicines and other healthy products.